AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2017
Nov 7, 2017
31542_dirs_2017-11-07_4f8150e5-5a85-4898-a736-e02427f4d860.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2017-11-06
Reporting Person: GRANDE ALICIA (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-06 | Common stock, par value $0.001 per share | M | 200000 | $0.47 | Acquired | 396346 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-06 | Options to purchase common stock | $0.47 | M | 200000 | Disposed | 2017-12-12 | Common Stock (200000) | Direct |
Footnotes
F1: The option was granted on December 12, 2012 and previously vested in three annual installments.
More from CATALYST PHARMACEUTICALS, INC.
Regulatory Filings
2026
Jun 23
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6